Welcome to our dedicated page for Forrester Resh SEC filings (Ticker: FORR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Looking for the numbers behind Forrester鈥檚 subscription renewals or curious when executives last sold shares? Our SEC filings hub answers those questions in minutes, not hours. Investors often search for 鈥淔orrester Research insider trading Form 4 transactions鈥� or 鈥淔orrester Research quarterly earnings report 10-Q filing鈥�. We bring every disclosure together and layer it with AI so you see the story behind the figures.
Skip the 200-page PDFs. Stock Titan鈥檚 platform delivers:
- AI-powered summaries that turn dense footnotes into plain language鈥攊deal for understanding Forrester Research SEC documents with AI
- AG真人官方-time alerts for Forrester Research Form 4 insider transactions real-time and 8-K headlines
- Side-by-side trend charts so you can compare research, consulting, and event revenue across quarters
The annual report鈥攕earchable as 鈥淔orrester Research annual report 10-K simplified鈥�鈥攂reaks down deferred revenue and contract liabilities. The 10-Q provides margin updates you鈥檒l need for a quick 鈥淔orrester Research earnings report filing analysis鈥�. Material announcements, like leadership changes, appear in 鈥淔orrester Research 8-K material events explained鈥�. If executive pay matters to you, the proxy鈥攐ften Googled as 鈥淔orrester Research proxy statement executive compensation鈥�鈥攊s parsed so you can scan option grants in seconds.
From Forrester Research executive stock transactions Form 4 to forward-looking risk factors, every filing is indexed and updated the moment it hits EDGAR. Use our export tools to monitor renewal ratios, track insider sentiment, and understand how event seasonality shapes cash flow鈥攁ll without wading through legal jargon. Complex disclosures, clarified.
Omeros Corporation (OMER) filed a Form 4 disclosing that non-employee director Dr. Leroy E. Hood received an annual stock-option grant for 15,000 shares on 27 Jun 2025. The option carries a $3.20 exercise price, a 10-year term expiring 27 Jun 2035, and will vest in full the day before the 2026 annual shareholder meeting provided he remains a director. No open-market purchases or sales of common stock were reported, and Table I shows no change in non-derivative share ownership. The filing reflects routine director compensation and represents a negligible portion of Omeros鈥� total shares outstanding, implying minimal immediate dilution or market impact.